spacer
spacer
Go to PDB code: 
protein ligands links
Lyase PDB-id
1c3s
    Jmol     Help!  
Contents
Description
Header details
Header records
References
PROCHECK
Protein chain
372 a.a. *
Ligands
SHH
Metal ions
_ZN
Waters ×142

* Residue conservation analysis
Tools
Image Generation
AstexViewer™@PDBe
Run PROCHECK
Clefts Calculation
  
PDB id: 1c3s
Name: Lyase
Title: Crystal structure of an hdac homolog complexed with saha

Structure:
Hdlp (histone deacetylase-like protein). Chain: a. Engineered: yes. Mutation: yes

Source:
Aquifex aeolicus. Organism_taxid: 63363. Expressed in: escherichia coli. Expression_system_taxid: 562.

UniProt:
O67135 (O67135_AQUAE) Pfam  
Seq:
Struc:
Seq: 375 a.a.
Struc: 372 a.a.*
Key:    PfamA domain
 Secondary structure  CATH domain
* PDB and UniProt seqs differ at 4 residue positions (black crosses)

Resolution:
2.50Å

R-factor:
0.200

R-free:
0.277

Authors:
M.S.Finnin,J.R.Donigian,N.P.Pavletich

Key ref:
M.S.Finnin et al. (1999). Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors.. Nature, 401, 188-193. [PubMed id: 10490031] [DOI: 10.1038/43710]

Date:
28-Jul-99

Release date:
15-Sep-99

Related entries:
1c3r
1c3s
Quick_links
RCSB
PDBe
SRS
MMDB
JenaLib
OCA
Proteopedia
CATH
SCOP
FSSP
HSSP
PDBSWS
PQS
ProSAT
Whatcheck
Procheck
Go to PROCHECK summary
Clefts
Clefts
Surface
RasMol surface
spacer
spacer

 
    Key reference    
 
 
DOI no: 10.1038/43710 Nature 401:188-193 (1999)
PubMed id: 10490031  
 
 
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors.
M.S.Finnin, J.R.Donigian, A.Cohen, V.M.Richon, R.A.Rifkind, P.A.Marks, R.Breslow, N.P.Pavletich.
 
  ABSTRACT  
 
Histone deacetylases (HDACs) mediate changes in nucleosome conformation and are important in the regulation of gene expression. HDACs are involved in cell-cycle progression and differentiation, and their deregulation is associated with several cancers. HDAC inhibitors, such as trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA), have anti-tumour effects, as they can inhibit cell growth, induce terminal differentiation and prevent the formation of tumours in mice models, and they are effective in the treatment of promyelocytic leukemia. Here we describe the structure of the histone deacetylase catalytic core, as revealed by the crystal structure of a homologue from the hyperthermophilic bacterium Aquifex aeolicus, that shares 35.2% identity with human HDAC1 over 375 residues, deacetylates histones in vitro and is inhibited by TSA and SAHA. The deacetylase, deacetylase-TSA and deacetylase-SAHA structures reveal an active site consisting of a tubular pocket, a zinc-binding site and two Asp-His charge-relay systems, and establish the mechanism of HDAC inhibition. The residues that make up the active site and contact the inhibitors are conserved across the HDAC family. These structures also suggest a mechanism for the deacetylation reaction and provide a framework for the further development of HDAC inhibitors as antitumour agents.
 
  Selected figure(s)  
 
Figure 3.
Figure 3 TSA binds inside the pocket making contacts to residues at the rim, walls and bottom of the pocket. a, Space-filling representation of TSA in the active-site pocket. The hydroxamic acid group, most of the aliphatic chain and part of the dimethylamino-phenyl group of TSA are buried (60% of TSA's surface area). The internal cavity has a volume of 144 ?3. b, Closeup stereo view of the structure of the HDLP-Zn2+-TSA complex in an orientation similar to Fig. 2a except for a 90° rotation about the vertical axis. TSA is in white; active-site residues and residues that contact TSA, which are all identical in HDAC1 except Tyr 91, are in yellow. c, Schematic representation of HDLP-TSA interactions. TSA is in black and the protein is in red. HDLP residues are labelled in red with their counterparts in HDAC1 indicated in black. Thatched semi-circles indicate van der Waals contacts between hydrophobic protein residues and TSA. Hydrogen bonds are shown as green dashed lines. d, Surface representation of the HDLP-TSA interface in a similar orientation to b. The protein surface is coloured according to residue identity with HDAC1. Cyan indicates residues that are identical in HDAC1.
Figure 4.
Figure 4 SAHA binds HDLP like TSA, but its aliphatic chain and cap groups make fewer contacts. Close-up view of the HDLP-Zn2+-SAHA complex in the same orientation and colour scheme as Fig. 3b. Note that Tyr 91 is not in the TSA-bound conformation.
 
  The above figures are reprinted by permission from Macmillan Publishers Ltd: Nature (1999, 401, 188-193) copyright 1999.  
  Figures were selected by an automated process.  

Literature references that cite this PDB file's key reference

  PubMed id Reference
19349466 A.Bougdour, D.Maubon, P.Baldacci, P.Ortet, O.Bastien, A.Bouillon, J.C.Barale, H.Pelloux, R.Ménard, and M.A.Hakimi (2009).
Drug inhibition of HDAC3 and epigenetic control of differentiation in Apicomplexa parasites.
  J Exp Med, 206, 953-966.  
19696806 A.Mukai, H.Komaki, M.Takagi, and K.Shin-ya (2009).
Novel siderophore, JBIR-16, isolated from Nocardia tenerifensis NBRC 101015.
  J Antibiot (Tokyo), 62, 601-603.  
19396896 A.P.Kozikowski, Y.Chen, T.Subhasish, N.E.Lewin, P.M.Blumberg, Z.Zhong, M.A.D'Annibale, W.L.Wang, Y.Shen, and B.Langley (2009).
Searching for disease modifiers-PKC activation and HDAC inhibition - a dual drug approach to Alzheimer's disease that decreases Abeta production while blocking oxidative stress.
  ChemMedChem, 4, 1095-1105.  
19169274 A.Zubia, S.Ropero, D.Otaegui, E.Ballestar, M.F.Fraga, M.Boix-Chornet, M.Berdasco, A.Martinez, L.Coll-Mulet, J.Gil, F.P.Cossío, and M.Esteller (2009).
Identification of (1H)-pyrroles as histone deacetylase inhibitors with antitumoral activity.
  Oncogene, 28, 1477-1484.  
  19794082 E.W.Schaefer, A.Loaiza-Bonilla, M.Juckett, J.F.DiPersio, V.Roy, J.Slack, W.Wu, K.Laumann, I.Espinoza-Delgado, and S.D.Gore (2009).
A phase 2 study of vorinostat in acute myeloid leukemia.
  Haematologica, 94, 1375-1382.  
19431162 F.Chen, A.H.Gao, J.Li, and F.J.Nan (2009).
Synthesis and biological evaluation of c7-demethyl largazole analogues.
  ChemMedChem, 4, 1269-1272.  
19536110 H.M.Wu, N.S.Tzeng, L.Qian, S.J.Wei, X.Hu, S.H.Chen, S.M.Rawls, P.Flood, J.S.Hong, and R.B.Lu (2009).
Novel neuroprotective mechanisms of memantine: increase in neurotrophic factor release from astroglia and anti-inflammation by preventing microglial activation.
  Neuropsychopharmacology, 34, 2344-2357.  
19197985 H.Nian, B.Delage, E.Ho, and R.H.Dashwood (2009).
Modulation of histone deacetylase activity by dietary isothiocyanates and allyl sulfides: studies with sulforaphane and garlic organosulfur compounds.
  Environ Mol Mutagen, 50, 213-221.  
19058176 J.Long, J.Zhao, Z.Yan, Z.Liu, and N.Wang (2009).
Antitumor effects of a novel sulfur-containing hydroxamate histone deacetylase inhibitor H40.
  Int J Cancer, 124, 1235-1244.  
19515748 L.Stimson, V.Wood, O.Khan, S.Fotheringham, and N.B.La Thangue (2009).
HDAC inhibitor-based therapies and haematological malignancy.
  Ann Oncol, 20, 1293-1302.  
19729656 N.C.Hait, J.Allegood, M.Maceyka, G.M.Strub, K.B.Harikumar, S.K.Singh, C.Luo, R.Marmorstein, T.Kordula, S.Milstien, and S.Spiegel (2009).
Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate.
  Science, 325, 1254-1257.  
19350240 N.Saban, and M.Bujak (2009).
Hydroxyurea and hydroxamic acid derivatives as antitumor drugs.
  Cancer Chemother Pharmacol, 64, 213-221.  
19459166 P.A.Marks, and W.S.Xu (2009).
Histone deacetylase inhibitors: Potential in cancer therapy.
  J Cell Biochem, 107, 600-608.  
19433508 P.H.Lee, K.L.Kuo, P.Y.Chu, E.M.Liu, and J.H.Lin (2009).
SLITHER: a web server for generating contiguous conformations of substrate molecules entering into deep active sites of proteins or migrating through channels in membrane transporters.
  Nucleic Acids Res, 37, W559-W564.  
19486511 S.Cang, Y.Ma, and D.Liu (2009).
New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer.
  J Hematol Oncol, 2, 22.  
19090524 S.Schäfer, L.Saunders, S.Schlimme, V.Valkov, J.M.Wagner, F.Kratz, W.Sippl, E.Verdin, and M.Jung (2009).
Pyridylalanine-containing hydroxamic acids as selective HDAC6 inhibitors.
  ChemMedChem, 4, 283-290.  
19779641 T.L.Newkirk, A.A.Bowers, and R.M.Williams (2009).
Discovery, biological activity, synthesis and potential therapeutic utility of naturally occurring histone deacetylase inhibitors.
  Nat Prod Rep, 26, 1293-1320.  
19721249 T.Suzuki (2009).
Explorative study on isoform-selective histone deacetylase inhibitors.
  Chem Pharm Bull (Tokyo), 57, 897-906.  
19317450 V.Patel, R.Mazitschek, B.Coleman, C.Nguyen, S.Urgaonkar, J.Cortese, R.H.Barker, E.Greenberg, W.Tang, J.E.Bradner, S.L.Schreiber, M.T.Duraisingh, D.F.Wirth, and J.Clardy (2009).
Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum.
  J Med Chem, 52, 2185-2187.  
  19484144 Y.T.Yang, C.Balch, S.K.Kulp, M.R.Mand, K.P.Nephew, and C.S.Chen (2009).
A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer.
  Neoplasia, 11, 552.  
18850582 A.Hrzenjak, M.L.Kremser, B.Strohmeier, F.Moinfar, K.Zatloukal, and H.Denk (2008).
SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway.
  J Pathol, 216, 495-504.  
18648687 A.I.Anzellotti, and N.P.Farrell (2008).
Zinc metalloproteins as medicinal targets.
  Chem Soc Rev, 37, 1629-1651.  
18568164 A.J.Vegas, J.H.Fuller, and A.N.Koehler (2008).
Small-molecule microarrays as tools in ligand discovery.
  Chem Soc Rev, 37, 1385-1394.  
18181121 A.P.Kozikowski, Y.Chen, A.M.Gaysin, D.N.Savoy, D.D.Billadeau, and K.H.Kim (2008).
Chemistry, biology, and QSAR studies of substituted biaryl hydroxamates and mercaptoacetamides as HDAC inhibitors-nanomolar-potency inhibitors of pancreatic cancer cell growth.
  ChemMedChem, 3, 487-501.  
18425819 A.Risch, and C.Plass (2008).
Lung cancer epigenetics and genetics.
  Int J Cancer, 123, 1-7.  
18285338 A.Schuetz, J.Min, A.Allali-Hassani, M.Schapira, M.Shuen, P.Loppnau, R.Mazitschek, N.P.Kwiatkowski, T.A.Lewis, R.L.Maglathin, T.H.McLean, A.Bochkarev, A.N.Plotnikov, M.Vedadi, and C.H.Arrowsmith (2008).
Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity.
  J Biol Chem, 283, 11355-11363.
PDB codes: 3c0y 3c0z 3c10
17593366 A.Tong, H.Zhang, Z.Li, L.Gou, Z.Wang, H.Wei, M.Tang, S.Liang, L.Chen, C.Huang, and Y.Wei (2008).
Proteomic analysis of liver cancer cells treated with suberonylanilide hydroxamic acid.
  Cancer Chemother Pharmacol, 61, 791-802.  
18568166 A.V.Bieliauskas, and M.K.Pflum (2008).
Isoform-selective histone deacetylase inhibitors.
  Chem Soc Rev, 37, 1402-1413.  
18710955 C.Haumaitre, O.Lenoir, and R.Scharfmann (2008).
Histone deacetylase inhibitors modify pancreatic cell fate determination and amplify endocrine progenitors.
  Mol Cell Biol, 28, 6373-6383.  
18616577 C.M.Lerche, P.A.Philipsen, M.Sehested, and H.C.Wulf (2008).
Photocarcinogenesis of topical tazarotene and isotretinoin alone and in combination with valproic acid in hairless mice.
  Exp Dermatol, 17, 972-974.  
17883328 C.Ptak, and A.Petronis (2008).
Epigenetics and complex disease: from etiology to new therapeutics.
  Annu Rev Pharmacol Toxicol, 48, 257-276.  
18398905 C.Yan, Z.Xiu, X.Li, S.Li, C.Hao, and H.Teng (2008).
Comparative molecular dynamics simulations of histone deacetylase-like protein: binding modes and free energy analysis to hydroxamic acid inhibitors.
  Proteins, 73, 134-149.  
18021260 G.W.Humphrey, Y.H.Wang, T.Hirai, R.Padmanabhan, D.M.Panchision, L.F.Newell, R.D.McKay, and B.H.Howard (2008).
Complementary roles for histone deacetylases 1, 2, and 3 in differentiation of pluripotent stem cells.
  Differentiation, 76, 348-356.  
18451556 H.Kobayashi, N.Morisaki, H.Miyachi, and Y.Hashimoto (2008).
Coordination of divalent metal cation to amide group to form adduct ion in FAB mass spectrometry: implication of Zn2+ in enzymatic hydrolysis of amide bond.
  Chem Pharm Bull (Tokyo), 56, 672-676.  
18469827 K.Strebhardt, A.Ullrich, and P.Ehrlich (2008).
Paul Ehrlich's magic bullet concept: 100 years of progress.
  Nat Rev Cancer, 8, 473-480.  
18212103 K.T.Andrews, T.N.Tran, A.J.Lucke, P.Kahnberg, G.T.Le, G.M.Boyle, D.L.Gardiner, T.S.Skinner-Adams, and D.P.Fairlie (2008).
Potent antimalarial activity of histone deacetylase inhibitor analogues.
  Antimicrob Agents Chemother, 52, 1454-1461.  
  18353181 L.Balakrishnan, and B.Milavetz (2008).
HDAC inhibitors stimulate viral transcription by multiple mechanisms.
  Virol J, 5, 43.  
18351681 M.J.Allen, J.P.Boyce, M.T.Trentalange, D.L.Treiber, B.Rasmussen, B.Tillotson, R.Davis, and P.Reddy (2008).
Identification of novel small molecule enhancers of protein production by cultured mammalian cells.
  Biotechnol Bioeng, 100, 1193-1204.  
18614528 M.J.Bottomley, P.Lo Surdo, P.Di Giovine, A.Cirillo, R.Scarpelli, F.Ferrigno, P.Jones, P.Neddermann, R.De Francesco, C.Steinkühler, P.Gallinari, and A.Carfí (2008).
Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain.
  J Biol Chem, 283, 26694-26704.
PDB codes: 2vqj 2vqm 2vqo 2vqq 2vqv 2vqw
18622098 M.Yoshida (2008).
[Chemical biology of HDAC (histone deacetylase) inhibitors]
  Nippon Yakurigaku Zasshi, 132, 18-21.  
19025622 N.B.Berry, and S.A.Bapat (2008).
Ovarian cancer plasticity and epigenomics in the acquisition of a stem-like phenotype.
  J Ovarian Res, 1, 8.  
18193082 O.Binda, C.Nassif, and P.E.Branton (2008).
SIRT1 negatively regulates HDAC1-dependent transcriptional repression by the RBP1 family of proteins.
  Oncogene, 27, 3384-3392.  
18839006 O.Khan, and N.B.La Thangue (2008).
Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas.
  Nat Clin Pract Oncol, 5, 714-726.  
18292778 X.J.Yang, and E.Seto (2008).
The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men.
  Nat Rev Mol Cell Biol, 9, 206-218.  
17956988 A.Lahm, C.Paolini, M.Pallaoro, M.C.Nardi, P.Jones, P.Neddermann, S.Sambucini, M.J.Bottomley, P.Lo Surdo, A.Carfí, U.Koch, R.De Francesco, C.Steinkühler, and P.Gallinari (2007).
Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases.
  Proc Natl Acad Sci U S A, 104, 17335-17340.  
17504020 A.Mai (2007).
The therapeutic uses of chromatin-modifying agents.
  Expert Opin Ther Targets, 11, 835-851.  
18081388 A.Olasz, K.Vanommeslaeghe, A.Krishtal, T.Veszprémi, C.Van Alsenoy, and P.Geerlings (2007).
The use of atomic intrinsic polarizabilities in the evaluation of the dispersion energy.
  J Chem Phys, 127, 224105.  
17721440 A.Vannini, C.Volpari, P.Gallinari, P.Jones, M.Mattu, A.Carfí, R.De Francesco, C.Steinkühler, and S.Di Marco (2007).
Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8-substrate complex.
  EMBO Rep, 8, 879-884.
PDB codes: 2v5w 2v5x
17726514 B.J.North, and E.Verdin (2007).
Interphase nucleo-cytoplasmic shuttling and localization of SIRT2 during mitosis.
  PLoS ONE, 2, e784.  
17377789 C.Hildmann, D.Riester, and A.Schwienhorst (2007).
Histone deacetylases--an important class of cellular regulators with a variety of functions.
  Appl Microbiol Biotechnol, 75, 487-497.  
17227860 C.M.Salisbury, and B.F.Cravatt (2007).
Activity-based probes for proteomic profiling of histone deacetylase complexes.
  Proc Natl Acad Sci U S A, 104, 1171-1176.  
17351388 C.Monneret (2007).
Histone deacetylase inhibitors for epigenetic therapy of cancer.
  Anticancer Drugs, 18, 363-370.  
17163561 F.E.Jacobsen, J.A.Lewis, and S.M.Cohen (2007).
The Design of Inhibitors for Medicinally Relevant Metalloproteins.
  ChemMedChem, 2, 152-171.  
17504013 J.A.Marwick, K.Ito, I.M.Adcock, and P.A.Kirkham (2007).
Oxidative stress and steroid resistance in asthma and COPD: pharmacological manipulation of HDAC-2 as a therapeutic strategy.
  Expert Opin Ther Targets, 11, 745-755.  
17661352 J.J.Westendorf (2007).
Histone deacetylases in control of skeletogenesis.
  J Cell Biochem, 102, 332-340.  
17464243 J.M.Mehnert, and W.K.Kelly (2007).
Histone deacetylase inhibitors: biology and mechanism of action.
  Cancer J, 13, 23-29.  
17179179 K.Kato, M.Miyaji-Yamaguchi, M.Okuwaki, and K.Nagata (2007).
Histone acetylation-independent transcription stimulation by a histone chaperone.
  Nucleic Acids Res, 35, 705-715.  
17665426 L.C.Huber, J.H.Distler, F.Moritz, H.Hemmatazad, T.Hauser, B.A.Michel, R.E.Gay, M.Matucci-Cerinic, S.Gay, O.Distler, and A.Jüngel (2007).
Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis.
  Arthritis Rheum, 56, 2755-2764.  
17694590 L.Gomez-Paloma, I.Bruno, E.Cini, S.Khochbin, M.Rodriquez, M.Taddei, S.Terracciano, and K.Sadoul (2007).
Design and Synthesis of Cyclopeptide Analogues of the Potent Histone Deacetylase Inhibitor FR235222.
  ChemMedChem, 2, 1511-1519.  
17265033 L.Larsen, M.Tonnesen, S.G.Ronn, J.Størling, S.Jørgensen, P.Mascagni, C.A.Dinarello, N.Billestrup, and T.Mandrup-Poulsen (2007).
Inhibition of histone deacetylases prevents cytokine-induced toxicity in beta cells.
  Diabetologia, 50, 779-789.  
17694086 M.Martin, R.Kettmann, and F.Dequiedt (2007).
Class IIa histone deacetylases: regulating the regulators.
  Oncogene, 26, 5450-5467.  
17690455 N.Aburai, Y.Esumi, H.Koshino, N.Nishizawa, and K.Kimura (2007).
Inhibitory activity of linoleic acid isolated from proso and Japanese millet toward histone deacetylase.
  Biosci Biotechnol Biochem, 71, 2061-2064.  
17322921 P.A.Marks (2007).
Discovery and development of SAHA as an anticancer agent.
  Oncogene, 26, 1351-1356.  
17211407 P.A.Marks, and R.Breslow (2007).
Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug.
  Nat Biotechnol, 25, 84-90.  
17325692 P.Gallinari, S.Di Marco, P.Jones, M.Pallaoro, and C.Steinkühler (2007).
HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics.
  Cell Res, 17, 195-211.  
17178833 R.Ikeda, C.Kokubu, K.Yusa, V.W.Keng, K.Horie, and J.Takeda (2007).
Sleeping beauty transposase has an affinity for heterochromatin conformation.
  Mol Cell Biol, 27, 1665-1676.  
17639084 R.L.Montgomery, C.A.Davis, M.J.Potthoff, M.Haberland, J.Fielitz, X.Qi, J.A.Hill, J.A.Richardson, and E.N.Olson (2007).
Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility.
  Genes Dev, 21, 1790-1802.  
17694092 S.C.Hodawadekar, and R.Marmorstein (2007).
Chemistry of acetyl transfer by histone modifying enzymes: structure, mechanism and implications for effector design.
  Oncogene, 26, 5528-5540.  
17627667 S.Kern, D.Riester, C.Hildmann, A.Schwienhorst, and F.J.Meyer-Almes (2007).
Inhibitor-mediated stabilization of the conformational structure of a histone deacetylase-like amidohydrolase.
  FEBS J, 274, 3578-3588.  
  17401192 T.K.Nielsen, C.Hildmann, D.Riester, D.Wegener, A.Schwienhorst, and R.Ficner (2007).
Complex structure of a bacterial class 2 histone deacetylase homologue with a trifluoromethylketone inhibitor.
  Acta Crystallogr Sect F Struct Biol Cryst Commun, 63, 270-273.
PDB code: 2gh6
17925016 T.M.Schroeder, A.K.Nair, R.Staggs, A.F.Lamblin, and J.J.Westendorf (2007).
Gene profile analysis of osteoblast genes differentially regulated by histone deacetylase inhibitors.
  BMC Genomics, 8, 362.  
17694088 W.Aufsatz, T.Stoiber, B.Rakic, and K.Naumann (2007).
Arabidopsis histone deacetylase 6: a green link to RNA silencing.
  Oncogene, 26, 5477-5488.  
17414513 W.G.Nelson (2007).
Prostate cancer prevention.
  Curr Opin Urol, 17, 157-167.  
17694093 W.S.Xu, R.B.Parmigiani, and P.A.Marks (2007).
Histone deacetylase inhibitors: molecular mechanisms of action.
  Oncogene, 26, 5541-5552.  
16485345 C.B.Yoo, and P.A.Jones (2006).
Epigenetic therapy of cancer: past, present and future.
  Nat Rev Drug Discov, 5, 37-50.  
16330553 C.Benjanirut, M.Paris, W.H.Wang, S.J.Hong, K.S.Kim, R.L.Hullinger, and O.M.Andrisani (2006).
The cAMP pathway in combination with BMP2 regulates Phox2a transcription via cAMP response element binding sites.
  J Biol Chem, 281, 2969-2981.  
  17219961 C.Sun, X.Liu, Y.Chen, and F.Liu (2006).
Anticancer activities of trichostatin A on maligant lymphoid cells.
  J Huazhong Univ Sci Technolog Med Sci, 26, 538-541.  
16855733 D.C.Juvale, V.V.Kulkarni, H.S.Deokar, N.K.Wagh, S.B.Padhye, and V.M.Kulkarni (2006).
3D-QSAR of histone deacetylase inhibitors: hydroxamate analogues.
  Org Biomol Chem, 4, 2858-2868.  
16795040 G.Iacomino, M.C.Medici, D.Napoli, and G.L.Russo (2006).
Effects of histone deacetylase inhibitors on p55CDC/Cdc20 expression in HT29 cell line.
  J Cell Biochem, 99, 1122-1131.  
16643606 H.Uchida, T.Maruyama, T.Nagashima, M.Ono, H.Masuda, T.Arase, I.Sugiura, M.Onouchi, T.Kajitani, H.Asada, and Y.Yoshimura (2006).
Human endometrial cytodifferentiation by histone deacetylase inhibitors.
  Hum Cell, 19, 38-42.  
16450343 H.Y.Lin, C.S.Chen, S.P.Lin, J.R.Weng, and C.S.Chen (2006).
Targeting histone deacetylase in cancer therapy.
  Med Res Rev, 26, 397-413.  
17108987 I.Collins, and P.Workman (2006).
New approaches to molecular cancer therapeutics.
  Nat Chem Biol, 2, 689-700.  
16757575 J.Han, L.Ding, B.Yuan, X.Yang, X.Wang, J.Li, Q.Lu, C.Huang, and Q.Ye (2006).
Hepatitis B virus X protein and the estrogen receptor variant lacking exon 5 inhibit estrogen receptor signaling in hepatoma cells.
  Nucleic Acids Res, 34, 3095-3106.  
16618385 K.W.Beekman, and M.Hussain (2006).
Targeted approaches for the management of metastatic prostate cancer.
  Curr Oncol Rep, 8, 206-212.  
17001696 L.Huang (2006).
Targeting histone deacetylases for the treatment of cancer and inflammatory diseases.
  J Cell Physiol, 209, 611-616.  
16652377 M.C.Myzak, E.Ho, and R.H.Dashwood (2006).
Dietary agents as histone deacetylase inhibitors.
  Mol Carcinog, 45, 443-446.  
16652385 M.Hernandez, Q.Shao, X.J.Yang, S.P.Luh, M.Kandouz, G.Batist, D.W.Laird, and M.A.Alaoui-Jamali (2006).
A histone deacetylation-dependent mechanism for transcriptional repression of the gap junction gene cx43 in prostate cancer cells.
  Prostate, 66, 1151-1161.  
16311994 M.Rodriquez, S.Terracciano, E.Cini, G.Settembrini, I.Bruno, G.Bifulco, M.Taddei, and L.Gomez-Paloma (2006).
Total synthesis, NMR solution structure, and binding model of the potent histone deacetylase inhibitor FR235222.
  Angew Chem Int Ed Engl, 45, 423-427.  
17022812 N.Kamath, P.Karwowska-Desaulniers, and M.K.Pflum (2006).
Limited proteolysis of human histone deacetylase 1.
  BMC Biochem, 7, 22.  
16456404 N.R.White, P.Mulligan, P.J.King, and I.R.Sanderson (2006).
Sodium butyrate-mediated Sp3 acetylation represses human insulin-like growth factor binding protein-3 expression in intestinal epithelial cells.
  J Pediatr Gastroenterol Nutr, 42, 134-141.  
16435156 P.A.Konstantinopoulos, G.P.Vandoros, and A.G.Papavassiliou (2006).
FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities.
  Cancer Chemother Pharmacol, 58, 711-715.  
16988654 R.Butler, and G.P.Bates (2006).
Histone deacetylase inhibitors as therapeutics for polyglutamine disorders.
  Nat Rev Neurosci, 7, 784-796.  
16397526 S.Minucci, and P.G.Pelicci (2006).
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer.
  Nat Rev Cancer, 6, 38-51.  
16462761 T.C.Karagiannis, and A.El-Osta (2006).
Modulation of cellular radiation responses by histone deacetylase inhibitors.
  Oncogene, 25, 3885-3893.  
17103016 T.Huhtiniemi, C.Wittekindt, T.Laitinen, J.Leppänen, A.Salminen, A.Poso, and M.Lahtela-Kakkonen (2006).
Comparative and pharmacophore model for deacetylase SIRT1.
  J Comput Aided Mol Des, 20, 589-599.  
16450389 V.Lakshmikanthan, I.Kaddour-Djebbar, R.W.Lewis, and M.V.Kumar (2006).
SAHA-sensitized prostate cancer cells to TNFalpha-related apoptosis-inducing ligand (TRAIL): mechanisms leading to synergistic apoptosis.
  Int J Cancer, 119, 221-228.  
16981208 Y.Nakao, S.Yoshida, S.Matsunaga, N.Shindoh, Y.Terada, K.Nagai, J.K.Yamashita, A.Ganesan, R.W.van Soest, and N.Fusetani (2006).
Azumamides A-E: histone deacetylase inhibitory cyclic tetrapeptides from the marine sponge Mycale izuensis.
  Angew Chem Int Ed Engl, 45, 7553-7557.  
16441228 Ã.˜.Bruserud, C.Stapnes, K.J.Tronstad, A.Ryningen, N.Anensen, and B.T.Gjertsen (2006).
Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML.
  Expert Opin Ther Targets, 10, 51-68.  
15717297 A.Mai, S.Massa, D.Rotili, I.Cerbara, S.Valente, R.Pezzi, S.Simeoni, and R.Ragno (2005).
Histone deacetylation in epigenetics: an attractive target for anticancer therapy.
  Med Res Rev, 25, 261-309.  
16149071 B.F.Curtin, L.M.Tetz, J.R.Compton, B.P.Doctor, R.K.Gordon, and M.P.Nambiar (2005).
Histone acetylase inhibitor trichostatin A induces acetylcholinesterase expression and protects against organophosphate exposure.
  J Cell Biochem, 96, 839-849.  
15822187 D.C.Drummond, C.O.Noble, D.B.Kirpotin, Z.Guo, G.K.Scott, and C.C.Benz (2005).
Clinical development of histone deacetylase inhibitors as anticancer agents.
  Annu Rev Pharmacol Toxicol, 45, 495-528.  
16557334 F.Leoni, G.Fossati, E.C.Lewis, J.K.Lee, G.Porro, P.Pagani, D.Modena, M.L.Moras, P.Pozzi, L.L.Reznikov, B.Siegmund, G.Fantuzzi, C.A.Dinarello, and P.Mascagni (2005).
The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo.
  Mol Med, 11, 1.  
15637150 J.S.Ungerstedt, Y.Sowa, W.S.Xu, Y.Shao, M.Dokmanovic, G.Perez, L.Ngo, A.Holmgren, X.Jiang, and P.A.Marks (2005).
Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors.
  Proc Natl Acad Sci U S A, 102, 673-678.  
16435576 K.M.Gilbert, S.R.Boger, P.Price, and E.K.Fifer (2005).
T cell tolerance induced by histone deacetylase inhibitor is mediated by P21cip1.
  Immunopharmacol Immunotoxicol, 27, 545-564.  
15898057 M.Biel, V.Wascholowski, and A.Giannis (2005).
Epigenetics--an epicenter of gene regulation: histones and histone-modifying enzymes.
  Angew Chem Int Ed Engl, 44, 3186-3216.  
16088937 M.Dokmanovic, and P.A.Marks (2005).
Prospects: histone deacetylase inhibitors.
  J Cell Biochem, 96, 293-304.  
15705580 M.Hernick, H.A.Gennadios, D.A.Whittington, K.M.Rusche, D.W.Christianson, and C.A.Fierke (2005).
UDP-3-O-((R)-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase functions through a general acid-base catalyst pair mechanism.
  J Biol Chem, 280, 16969-16978.
PDB codes: 1yh8 1yhc
15734731 M.K.Tripathi, S.Misra, S.V.Khedkar, N.Hamilton, C.Irvin-Wilson, C.Sharan, L.Sealy, and G.Chaudhuri (2005).
Regulation of BRCA2 gene expression by the SLUG repressor protein in human breast cells.
  J Biol Chem, 280, 17163-17171.  
15723344 P.S.Espino, B.Drobic, K.L.Dunn, and J.R.Davie (2005).
Histone modifications as a platform for cancer therapy.
  J Cell Biochem, 94, 1088-1102.  
15915507 S.Ronzoni, M.Faretta, M.Ballarini, P.Pelicci, and S.Minucci (2005).
New method to detect histone acetylation levels by flow cytometry.
  Cytometry A, 66, 52-61.  
16041839 S.Schäfer, and M.Jung (2005).
Chromatin modifications as targets for new anticancer drugs.
  Arch Pharm (Weinheim), 338, 347-357.  
15863892 T.Maeda, Y.Nagaoka, Y.Kawai, N.Takagaki, C.Yasuda, S.Yogosawa, Y.Sowa, T.Sakai, and S.Uesato (2005).
Inhibitory effects of cancer cell proliferation by novel histone deacetylase inhibitors involve p21/WAF1 induction and G2/M arrest.
  Biol Pharm Bull, 28, 849-853.  
16264908 W.K.Kelly, and P.A.Marks (2005).
Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid.
  Nat Clin Pract Oncol, 2, 150-157.  
15964800 Y.Dai, M.Rahmani, P.Dent, and S.Grant (2005).
Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation.
  Mol Cell Biol, 25, 5429-5444.  
15477595 A.Vannini, C.Volpari, G.Filocamo, E.C.Casavola, M.Brunetti, D.Renzoni, P.Chakravarty, C.Paolini, R.De Francesco, P.Gallinari, C.Steinkühler, and S.Di Marco (2004).
Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor.
  Proc Natl Acad Sci U S A, 101, 15064-15069.
PDB code: 1w22
15352027 A.Villar-Garea, and M.Esteller (2004).
Histone deacetylase inhibitors: understanding a new wave of anticancer agents.
  Int J Cancer, 112, 171-178.  
15128440 B.J.North, and E.Verdin (2004).
Sirtuins: Sir2-related NAD-dependent protein deacetylases.
  Genome Biol, 5, 224.  
15060035 C.Hildmann, M.Ninkovic, R.Dietrich, D.Wegener, D.Riester, T.Zimmermann, O.M.Birch, C.Bernegger, P.Loidl, and A.Schwienhorst (2004).
A new amidohydrolase from Bordetella or Alcaligenes strain FB188 with similarities to histone deacetylases.
  J Bacteriol, 186, 2328-2339.  
14695887 C.S.Mitsiades, N.S.Mitsiades, C.J.McMullan, V.Poulaki, R.Shringarpure, T.Hideshima, M.Akiyama, D.Chauhan, N.Munshi, X.Gu, C.Bailey, M.Joseph, T.A.Libermann, V.M.Richon, P.A.Marks, and K.C.Anderson (2004).
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications.
  Proc Natl Acad Sci U S A, 101, 540-545.  
14734806 C.Y.Gui, L.Ngo, W.S.Xu, V.M.Richon, and P.A.Marks (2004).
Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1.
  Proc Natl Acad Sci U S A, 101, 1241-1246.  
14701748 H.Lee, N.Rezai-Zadeh, and E.Seto (2004).
Negative regulation of histone deacetylase 8 activity by cyclic AMP-dependent protein kinase A.
  Mol Cell Biol, 24, 765-773.  
15662999 H.Park, and S.Lee (2004).
Homology modeling, force field design, and free energy simulation studies to optimize the activities of histone deacetylase inhibitors.
  J Comput Aided Mol Des, 18, 375-388.  
15467184 H.S.Lee, M.H.Park, S.J.Yang, H.Y.Jung, S.S.Byun, D.S.Lee, H.S.Yoo, Y.I.Yeom, and S.B.Seo (2004).
Gene expression analysis in human gastric cancer cell line treated with trichostatin A and S-adenosyl-L-homocysteine using cDNA microarray.
  Biol Pharm Bull, 27, 1497-1503.  
15283467 K.E.Joung, D.K.Kim, and Y.Y.Sheen (2004).
Antiproliferative effect of trichostatin A and HC-toxin in T47D human breast cancer cells.
  Arch Pharm Res, 27, 640-645.  
15202563 K.N.Min, M.J.Cho, D.K.Kim, and Y.Y.Sheen (2004).
Estrogen receptor enhances the antiproliferative effects of trichostatin A and HC-toxin in human breast cancer cells.
  Arch Pharm Res, 27, 554-561.  
15476220 K.Nishida, T.Komiyama, S.Miyazawa, Z.N.Shen, T.Furumatsu, H.Doi, A.Yoshida, J.Yamana, M.Yamamura, Y.Ninomiya, H.Inoue, and H.Asahara (2004).
Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression.
  Arthritis Rheum, 50, 3365-3376.  
15297880 L.Thevenet, C.Méjean, B.Moniot, N.Bonneaud, N.Galéotti, G.Aldrian-Herrada, F.Poulat, P.Berta, M.Benkirane, and B.Boizet-Bonhoure (2004).
Regulation of human SRY subcellular distribution by its acetylation/deacetylation.
  EMBO J, 23, 3336-3345.  
15155140 R.Kristeleit, L.Stimson, P.Workman, and W.Aherne (2004).
Histone modification enzymes: novel targets for cancer drugs.
  Expert Opin Emerg Drugs, 9, 135-154.  
15230695 S.Eyal, B.Yagen, E.Sobol, Y.Altschuler, M.Shmuel, and M.Bialer (2004).
The activity of antiepileptic drugs as histone deacetylase inhibitors.
  Epilepsia, 45, 737-744.  
15157277 S.M.Nelson, L.R.Ferguson, and W.A.Denny (2004).
DNA and the chromosome - varied targets for chemotherapy.
  Cell Chromosome, 3, 2.  
15016799 V.Pennaneach, V.Barbier, K.Regazzoni, R.Fotedar, and A.Fotedar (2004).
Rb inhibits E2F-1-induced cell death in a LXCXE-dependent manner by active repression.
  J Biol Chem, 279, 23376-23383.  
12833153 B.E.Coggins, X.Li, A.L.McClerren, O.Hindsgaul, C.R.Raetz, and P.Zhou (2003).
Structure of the LpxC deacetylase with a bound substrate-analog inhibitor.
  Nat Struct Biol, 10, 645-651.
PDB code: 1nzt
12761226 C.L.Antos, T.A.McKinsey, M.Dreitz, L.M.Hollingsworth, C.L.Zhang, K.Schreiber, H.Rindt, R.J.Gorczynski, and E.N.Olson (2003).
Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors.
  J Biol Chem, 278, 28930-28937.  
12819349 D.A.Whittington, K.M.Rusche, H.Shin, C.A.Fierke, and D.W.Christianson (2003).
Crystal structure of LpxC, a zinc-dependent deacetylase essential for endotoxin biosynthesis.
  Proc Natl Acad Sci U S A, 100, 8146-8150.
PDB code: 1p42
12913293 H.Takigawa-Imamura, T.Sekine, M.Murata, K.Takayama, K.Nakazawa, and J.Nakagawa (2003).
Stimulation of glucose uptake in muscle cells by prolonged treatment with scriptide, a histone deacetylase inhibitor.
  Biosci Biotechnol Biochem, 67, 1499-1506.  
14502267 K.Zhao, X.Chai, A.Clements, and R.Marmorstein (2003).
Structure and autoregulation of the yeast Hst2 homolog of Sir2.
  Nat Struct Biol, 10, 864-871.
PDB code: 1q14
14522996 M.D.Jackson, M.T.Schmidt, N.J.Oppenheimer, and J.M.Denu (2003).
Mechanism of nicotinamide inhibition and transglycosidation by Sir2 histone/protein deacetylases.
  J Biol Chem, 278, 50985-50998.  
  12724234 M.Verma, B.K.Dunn, S.Ross, P.Jain, W.Wang, R.Hayes, and A.Umar (2003).
Early detection and risk assessment: proceedings and recommendations from the Workshop on Epigenetics in Cancer Prevention.
  Ann N Y Acad Sci, 983, 298-319.  
12817474 N.Klan, S.Seuter, N.Schnur, M.Jung, and D.Steinhilber (2003).
Trichostatin A and structurally related histone deacetylase inhibitors induce 5-lipoxygenase promoter activity.
  Biol Chem, 384, 777-785.  
  12724214 S.Thiagalingam, K.H.Cheng, H.J.Lee, N.Mineva, A.Thiagalingam, and J.F.Ponte (2003).
Histone deacetylases: unique players in shaping the epigenetic histone code.
  Ann N Y Acad Sci, 983, 84.  
12606581 Y.Zhang, N.Li, C.Caron, G.Matthias, D.Hess, S.Khochbin, and P.Matthias (2003).
HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo.
  EMBO J, 22, 1168-1179.  
11979447 A.A.Ruefli, D.Bernhard, K.M.Tainton, R.Kofler, M.J.Smyth, and R.W.Johnstone (2002).
Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-glycoprotein-expressing cells.
  Int J Cancer, 99, 292-298.  
12105181 A.D.Weston, R.A.Chandraratna, J.Torchia, and T.M.Underhill (2002).
Requirement for RAR-mediated gene repression in skeletal progenitor differentiation.
  J Cell Biol, 158, 39-51.  
12100550 A.K.Ingram, and D.Horn (2002).
Histone deacetylases in Trypanosoma brucei: two are essential and another is required for normal cell cycle progression.
  Mol Microbiol, 45, 89-97.  
12042707 A.Melnick, and J.D.Licht (2002).
Histone deacetylases as therapeutic targets in hematologic malignancies.
  Curr Opin Hematol, 9, 322-332.  
12391296 A.N.Poux, M.Cebrat, C.M.Kim, P.A.Cole, and R.Marmorstein (2002).
Structure of the GCN5 histone acetyltransferase bound to a bisubstrate inhibitor.
  Proc Natl Acad Sci U S A, 99, 14065-14070.
PDB code: 1m1d
11726666 A.R.Guardiola, and T.P.Yao (2002).
Molecular cloning and characterization of a novel histone deacetylase HDAC10.
  J Biol Chem, 277, 3350-3356.  
12186850 B.Schwer, B.J.North, R.A.Frye, M.Ott, and E.Verdin (2002).
The human silent information regulator (Sir)2 homologue hSIRT3 is a mitochondrial nicotinamide adenine dinucleotide-dependent deacetylase.
  J Cell Biol, 158, 647-657.  
11739383 D.D.Fischer, R.Cai, U.Bhatia, F.A.Asselbergs, C.Song, R.Terry, N.Trogani, R.Widmer, P.Atadja, and D.Cohen (2002).
Isolation and characterization of a novel class II histone deacetylase, HDAC10.
  J Biol Chem, 277, 6656-6666.  
11914636 D.M.Vigushin, and R.C.Coombes (2002).
Histone deacetylase inhibitors in cancer treatment.
  Anticancer Drugs, 13, 1.  
11867742 F.Leoni, A.Zaliani, G.Bertolini, G.Porro, P.Pagani, P.Pozzi, G.Donà, G.Fossati, S.Sozzani, T.Azam, P.Bufler, G.Fantuzzi, I.Goncharov, S.H.Kim, B.J.Pomerantz, L.L.Reznikov, B.Siegmund, C.A.Dinarello, and P.Mascagni (2002).
The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines.
  Proc Natl Acad Sci U S A, 99, 2995-3000.  
11940654 G.He, and D.M.Margolis (2002).
Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat.
  Mol Cell Biol, 22, 2965-2973.  
11948178 L.Gao, M.A.Cueto, F.Asselbergs, and P.Atadja (2002).
Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family.
  J Biol Chem, 277, 25748-25755.  
12110674 N.Adachi, A.Kimura, and M.Horikoshi (2002).
A conserved motif common to the histone acetyltransferase Esa1 and the histone deacetylase Rpd3.
  J Biol Chem, 277, 35688-35695.  
11884604 P.Bjerling, R.A.Silverstein, G.Thon, A.Caudy, S.Grewal, and K.Ekwall (2002).
Functional divergence between histone deacetylases in fission yeast by distinct cellular localization and in vivo specificity.
  Mol Cell Biol, 22, 2170-2181.  
11940660 P.Dufourcq, M.Victor, F.Gay, D.Calvo, J.Hodgkin, and Y.Shi (2002).
Functional requirement for histone deacetylase 1 in Caenorhabditis elegans gonadogenesis.
  Mol Cell Biol, 22, 3024-3034.  
11986315 P.Gélébart, T.Kovács, J.P.Brouland, R.van Gorp, J.Grossmann, N.Rivard, Y.Panis, V.Martin, R.Bredoux, J.Enouf, and B.Papp (2002).
Expression of endomembrane calcium pumps in colon and gastric cancer cells. Induction of SERCA3 expression during differentiation.
  J Biol Chem, 277, 26310-26320.  
12120280 R.W.Johnstone (2002).
Histone-deacetylase inhibitors: novel drugs for the treatment of cancer.
  Nat Rev Drug Discov, 1, 287-299.  
12457432 W.K.Kelly, O.A.O'Connor, and P.A.Marks (2002).
Histone deacetylase inhibitors: from target to clinical trials.
  Expert Opin Investig Drugs, 11, 1695-1713.  
16232949 C.Liu, I.Chu, and S.Hwang (2001).
Pentanoic acid, a novel protein synthesis stimulant for Chinese Hamster Ovary (CHO) cells.
  J Biosci Bioeng, 91, 71-75.  
11483616 C.M.Grozinger, E.D.Chao, H.E.Blackwell, D.Moazed, and S.L.Schreiber (2001).
Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening.
  J Biol Chem, 276, 38837-38843.  
11134535 J.C.Tanny, and D.Moazed (2001).
Coupling of histone deacetylation to NAD breakdown by the yeast silencing protein Sir2: Evidence for acetyl transfer from substrate to an NAD breakdown product.
  Proc Natl Acad Sci U S A, 98, 415-420.  
11148046 J.E.Jackman, C.R.Raetz, and C.A.Fierke (2001).
Site-directed mutagenesis of the bacterial metalloamidase UDP-(3-O-acyl)-N-acetylglucosamine deacetylase (LpxC). Identification of the zinc binding site.
  Biochemistry, 40, 514-523.  
11668605 L.M.Sachs, T.Amano, N.Rouse, and Y.B.Shi (2001).
Involvement of histone deacetylase at two distinct steps in gene regulation during intestinal development in Xenopus laevis.
  Dev Dyn, 222, 280-291.  
11742974 M.Göttlicher, S.Minucci, P.Zhu, O.H.Krämer, A.Schimpf, S.Giavara, J.P.Sleeman, F.Lo Coco, C.Nervi, P.G.Pelicci, and T.Heinzel (2001).
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells.
  EMBO J, 20, 6969-6978.  
11602581 M.K.Pflum, J.K.Tong, W.S.Lane, and S.L.Schreiber (2001).
Histone deacetylase 1 phosphorylation promotes enzymatic activity and complex formation.
  J Biol Chem, 276, 47733-47741.  
11226290 N.Mishra, D.R.Brown, I.M.Olorenshaw, and G.M.Kammer (2001).
Trichostatin A reverses skewed expression of CD154, interleukin-10, and interferon-gamma gene and protein expression in lupus T cells.
  Proc Natl Acad Sci U S A, 98, 2628-2633.  
11134513 R.Furumai, Y.Komatsu, N.Nishino, S.Khochbin, M.Yoshida, and S.Horinouchi (2001).
Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin.
  Proc Natl Acad Sci U S A, 98, 87-92.  
11125048 S.Dietmann, J.Park, C.Notredame, A.Heger, M.Lappe, and L.Holm (2001).
A fully automatic evolutionary classification of protein folds: Dali Domain Dictionary version 3.
  Nucleic Acids Res, 29, 55-57.  
11106353 C.A.Johnson (2000).
Chromatin modification and disease.
  J Med Genet, 37, 905-915.  
10753902 J.E.Jackman, C.A.Fierke, L.N.Tumey, M.Pirrung, T.Uchiyama, S.H.Tahir, O.Hindsgaul, and C.R.Raetz (2000).
Antibacterial agents that target lipid A biosynthesis in gram-negative bacteria. Inhibition of diverse UDP-3-O-(r-3-hydroxymyristoyl)-n-acetylglucosamine deacetylases by substrate analogs containing zinc binding motifs.
  J Biol Chem, 275, 11002-11009.  
10984530 M.Downes, P.Ordentlich, H.Y.Kao, J.G.Alvarez, and R.M.Evans (2000).
Identification of a nuclear domain with deacetylase activity.
  Proc Natl Acad Sci U S A, 97, 10330-10335.  
11199916 M.Jung (2000).
[Inhibitors of histone deacetylase as new agents for prevention and treatment of cancer] .
  Pharm Unserer Zeit, 29, 385-388.  
10954755 V.M.Richon, T.W.Sandhoff, R.A.Rifkind, and P.A.Marks (2000).
Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation.
  Proc Natl Acad Sci U S A, 97, 10014-10019.  
10655483 X.Zhou, V.M.Richon, R.A.Rifkind, and P.A.Marks (2000).
Identification of a transcriptional repressor related to the noncatalytic domain of histone deacetylases 4 and 5.
  Proc Natl Acad Sci U S A, 97, 1056-1061.  
The most recent references are shown first. Citation data come partly from CiteXplore and partly from an automated harvesting procedure. Note that this is likely to be only a partial list as not all journals are covered by either method. However, we are continually building up the citation data so more and more references will be included with time. Where a reference describes a PDB structure, the PDB codes are shown on the right.